DURGA-2

A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma

Near Add Your Location

Sorting 9 by

Colorado Blood Cancer Institute
Sarah Cannon at Presbyterian/St. Luke's Medical Center (HealthONE)
Denver, CO
  • Accepting patients
  • Show Principal Investigator
City of Hope Comprehensive Cancer Center
Beckman Research Institute
Duarte, CA
  • Accepting patients
Alvin J. Siteman Cancer Center
Washington University Medical Campus
St. Louis, MO
  • Accepting patients
Moffitt Cancer Center
Magnolia Campus
Tampa, FL
  • Accepting patients
Tennessee Oncology - Hayes
Nashville, TN
  • Accepting patients
Winship Cancer Institute
Emory University
Atlanta, GA
  • Not yet accepting
New York University Langone Medical Center
Laura and Isaac Perlmutter Cancer Center
New York, NY
  • Accepting patients
UVA Cancer Center
University of Virginia Health System
Charlottesville, VA
  • Accepting patients
Holden Comprehensive Cancer Center - University of Iowa
University of Iowa Hospitals and Clinics
Iowa City, IA
  • Accepting patients

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.